Prostate cancer- ASCO 22 and templates

 

Practice changing trials

1. ARASENS

2. PROPEL

3. MAGNITUDE

References:

1. ARASENS: https://www.nejm.org/doi/full/10.1056/NEJMoa2119115

2. PROPEL: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.011

3. MAGNITUDE: https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.6_suppl.012

Metastatic castrate resistant prostate cancer mCRPC

metastatic castration sensitive prostate cancer mCSPC

Biochemical progression M0 

High risk prostate cancer- adjuvant treatment